Aldeyra CDO Stephen Machatha resigns; transition through March 2026 with $176K severance

Aldeyra Therapeutics, Inc.

Chief Development Officer Stephen G. Machatha voluntarily resigns effective on/before March 31, 2026.
Machatha to remain employed through transition period to ensure smooth handoff.
Severance includes $88K lump sum (50% of 2025 bonus at 110% of target) plus another $88K on release.
No dispute with management cited as reason for departure.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.